Analytical Data
-
Gene name
CDK13-CCNK
- Application
-
Species
Human
-
Source
Baculovirus
-
Tag
N-GST;N-Flag
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q14004-1 (Q673-S1054)&O75909-1
-
Expression Region
Q14004-1 (Q673-S1054)&O75909-1 (M1-S300)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK13-CCNK recombinant proteins have emerged as significant subjects of research due to their critical roles in regulating transcription and cell cycle progression. CDK13 (Cyclin-Dependent Kinase 13) is a key player in the phosphorylation of the C-terminal domain of RNA polymerase II, influencing gene expression and RNA processing. Its partner, CCNK (Cyclin C-Dependent Kinase Subunit), modulates CDK13 activity, forming a functional complex that affects various cellular processes, including differentiation and proliferation. Dysregulation of this complex has been implicated in numerous diseases, particularly cancer, where aberrant transcriptional control contributes to tumorigenesis. Understanding the structure and function of CDK13-CCNK recombinant proteins can shed light on their mechanistic pathways and potential therapeutic targets. Research in this area aims to delineate their interactions, identify downstream effectors, and explore their implications in normal physiology and disease states. As a result, CDK13-CCNK recombinant proteins hold promise not only for advancing fundamental biological knowledge but also for developing innovative strategies in targeted cancer therapies.
